The ANKZF1 Knockout A-549 Polyclonal Cells product is a heterogeneous pool of cells generated by CRISPR/Cas9-mediated disruption of the ANKZF1 gene in the A-549 human lung adenocarcinoma cell line. This polyclonal knockout population serves as a genetically defined loss-of-function model, enabling functional investigation of ANKZF1 without reliance on transient suppression methods. The edited cells retain the epithelial characteristics of the parental line while lacking ANKZF1 protein expression, making them suitable for a wide range of phenotypic and mechanistic studies.
The A-549 cell line, originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma, is a well-characterized model of non-small cell lung cancer (NSCLC). These adherent epithelial cells harbor KRAS and TP53 mutations and exhibit features of alveolar basal epithelium. They are extensively employed in cancer biology, drug metabolism, and respiratory disease research. In the context of ANKZF1 knockout, the A-549 background provides a physiologically relevant platform to study mitochondrial quality control and ribosome-associated protein quality control (RQC) in cancer cell metabolism and stress response.
ANKZF1 functions as a critical node connecting cytoplasmic translation quality control and mitochondrial homeostasis. Localized to the mitochondrial outer membrane, it senses ribosome stalling and, in complex with RQC factors TCF25 and NEMF, catalyzes endonucleolytic cleavage of peptidyl-tRNA. This activity, coupled with the mechanical force of VCP/p97, extracts stalled nascent chains for ubiquitin-proteasome-dependent degradation. Concurrently, ANKZF1 regulates mitochondrial dynamics by modulating the activity of fusion proteins OPA1 and fission protein DRP1, thereby influencing mitophagy and mitochondrial network integrity. Upstream signals activating ANKZF1 include mitochondrial stress, unfolded protein response, and elevated reactive oxygen species.
In A-549 NSCLC cells, ANKZF1 is implicated in balancing mitochondrial quality control and proteostatic stress responses. Dysregulation of RQC and mitochondrial dynamics is a hallmark of cancer, contributing to metabolic adaptation, drug resistance, and evasion of apoptosis. The ANKZF1 knockout polyclonal population allows dissection of these pathways specifically within lung adenocarcinoma, where mitochondrial dysfunction is linked to tumor progression. By disrupting ANKZF1, researchers can assess its role in maintaining mitochondrial membrane potential, ATP production, and apoptotic sensitivity, as well as its impact on the response to chemotherapeutic agents.
This knockout model supports a broad array of experimental applications, from examining mitochondrial morphology via immunofluorescence and assessing apoptosis through flow cytometry, to co-immunoprecipitation studies mapping interactions with RQC1, RQC2, and VCP/p97. It is ideal for metabolic flux analyses and drug sensitivity screens, where ANKZF1 deficiency may reveal vulnerabilities in NSCLC cells. RT-qPCR and western blotting enable systematic profiling of RQC pathway components and mitochondrial gene expression changes. For comprehensive technical support and application guidance, please contact Ascent Research.
